Epstein-Barr Virus Infections × Clear all
NCT07358910 2026-01-22

RACSMEI

Institut Pasteur du Cambodge

Recruiting
10,000 enrolled
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Atara Biotherapeutics

Phase 1/2 Terminated
12 enrolled 8 charts